Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Evaluating the analytical performance of direct-to-consumer gut microbiome testing services (Nature)
- Resecting a Rectal Carcinoid (GI & Endoscopy News)
- AI blood test detects early pancreatic cancer with up to 94% accuracy (Medical Xpress)
- Why 2026 is a reset year for U.S. health care (Medical Economics)
- The “Dream Team” for Managing IBS-C Needs GI Psychologist and Dietician (Gastroenterology Learning Network)
- March 2026 issue Of The American Journal of Gastroenterology (The American Journal of Gastroenterology)
- The GI physician shortage by state, by 2036 (Becker’s GI & Endoscopy)
- PAGI Joins UPMC to Expand Access to Specialized Gastroenterology Care in Central Pa. (UPMC)
